Tumor hypoxia and reoxygenation: the yin and yang for radiotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Tumor hypoxia, a common feature occurring in nearly all human solid tumors is a major contributing factor for failures of anticancer therapies. Because ionizing radiation depends heavily on the presence of molecular oxygen to produce cytotoxic effect, the negative impact of tumor hypoxia had long been recognized. In this review, we will highlight some of the past attempts to overcome tumor hypoxia including hypoxic radiosensitizers and hypoxia-selective cytotoxin. Although they were (still are) a very clever idea, they lacked clinical efficacy largely because of 'reoxygenation' phenomenon occurring in the conventional low dose hyperfractionation radiotherapy prevented proper activation of these compounds. Recent meta-analysis and imaging studies do however indicate that there may be a significant clinical benefit in lowering the locoregional failures by using these compounds. Latest technological advancement in radiotherapy has allowed to deliver high doses of radiation conformally to the tumor volume. Although this technology has brought superb clinical responses for many types of cancer, recent modeling studies have predicted that tumor hypoxia is even more serious because 'reoxygenation' is low thereby leaving a large portion of hypoxic tumor cells behind. Wouldn't it be then reasonable to combine hypoxic radiosensitizers and/or hypoxia-selective cytotoxin with the latest radiotherapy? We will provide some preclinical and clinical evidence to support this idea hoping to revamp an enthusiasm for hypoxic radiosensitizers or hypoxia-selective cytotoxins as an adjunct therapy for radiotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828 · cited 5×
“In the absence of O2, DNA radicals are repaired by abstracting hydrogen from sulfhydryl (SH) group present in protein [4].”
BackgroundMethodInfluentialSemenza, G. L., & Wang, G. L. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5447 · Cited by 2,617
Noman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Direct measurement of local oxygen concentration in the bone marrow of live animals
Spencer, J. A., Ferraro, F., Roussakis, E., Klein, A., Wu, J., Runnels, J. M., Zaher, W., Mortensen, L. J., Alt, C., Turcotte, R., et al. (2014) · Nature · doi:10.1038/nature13034 · Cited by 1,167 · cited 1×
“A platinum complex of porphyrin complexes has recently demonstrated low yet heterogeneous oxygen tension distributions in the bone marrow of mice by using phosphorescence lifetime imaging [61].”
Overgaard, J. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.03.004 · Cited by 456
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380 · cited 9×
“With the exhausted enthusiasm for hypoxic radiosensitizers, misonidazole is currently being utilized in the clinic as a positron-emission tomography (PET) [29] probe detecting tumor hypoxia [30] and pimonidazole, also known as ‘hypoxyprobe’ is being used to detect the tissue hypoxia in the pre-clinical setting [31].”
BackgroundMethodResultInfluential
Cited by
Tracking tumor biology with radiomics: a systematic review utilizing a radiomics quality score
Sanduleanu, S., Woodruff, H. C., de Jong, E. E. C., van Timmeren, J. E., Jochems, A., Dubois, L., & Lambin, P. (2018) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2018.03.033 · Cited by 242
“, the hypoxia PET-tracers FMISO, FAZA and HX4), has led to recent enthusiasm for hypoxic radio-sensitizers and hypoxia-selective cytotoxins as an adjunct therapy before tumor irradiation [65].”
BackgroundYang, S., Tang, Z., Hu, C., Zhang, D., Shen, N., Yu, H., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201805955 · Cited by 210
Jiang, W., Zhang, Z., Wang, Q., Dou, J., Zhao, Y., Ma, Y., Liu, H., Xu, H., & Wang, Y. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b01458 · Cited by 146
The regulation of immune checkpoints by the hypoxic tumor microenvironment
Hu, M., Li, Y., Lu, Y., Wang, M., Li, Y., Wang, C., Li, Q., & Zhao, H. (2021) · PeerJ · doi:10.7717/peerj.11306 · Cited by 51
Metadata
- Authors
- Hong, B.-J., Kim, J., Jeong, H., Bok, S., Kim, Y.-E., & Ahn, G.-O.
- Venue
- Radiation Oncology Journal
- Published
- 2016-12-31
- Volume
- 34
- Issue
- 4
- Pages
- 239-249
- ISSN
- 1229-8719 (ISSN-L)
- 2234-1900
- 2234-3156
- OpenAlex
- W2563569367
- Cited by
- 63
- References
- 7
- FWCI
- 2.79
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.